These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 2409720

  • 1. [Polish preparations for preventing and treating infections caused by Pseudomonas aeruginosa].
    Schiller B, Buchowicz I, Lysakowska E, Sakiel S, Korbecki M.
    Zh Mikrobiol Epidemiol Immunobiol; 1985 Apr; (4):30-2. PubMed ID: 2409720
    [Abstract] [Full Text] [Related]

  • 2. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy.
    Lee NG, Jung SB, Ahn BY, Kim YH, Kim JJ, Kim DK, Kim IS, Yoon SM, Nam SW, Kim HS, Park WJ.
    Vaccine; 2000 Mar 17; 18(18):1952-61. PubMed ID: 10699346
    [Abstract] [Full Text] [Related]

  • 3. [Results of using polyvalent Pseudomonas aeruginosa vaccine in children with burns by various medical centers].
    Bbukowska D, Serafińska D, Rudowski W, Hoffman S, Olański W, Gardzińska E, Popiel D, Jedrzejczak G, Czarnecka I.
    Pol Tyg Lek; 2000 Mar 17; 44(43-45):924-7. PubMed ID: 2518666
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Active and passive immunization with Pseudomonas aeruginosa ribosomal vaccines and antisera in the burned rat model.
    Lieberman MM, Walker HL, Ayala E, Chapa I.
    J Surg Res; 1986 Feb 17; 40(2):138-44. PubMed ID: 3080639
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Effectiveness of tobramycin and immunologic preparations in experimental Pseudomonas infection].
    Minukhin VV, Tsyganenko AIa.
    Antibiot Khimioter; 1989 Apr 17; 34(4):282-6. PubMed ID: 2502083
    [Abstract] [Full Text] [Related]

  • 8. [Experimental basis for the combined use of tobramycin and immune preparations for treating acute Pseudomonas aeruginosa infections].
    Minukhin VV, Tsyganenko VIa.
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Aug 17; (8):42-5. PubMed ID: 3094301
    [Abstract] [Full Text] [Related]

  • 9. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.
    Zaidi TS, Priebe GP, Pier GB.
    Infect Immun; 2006 Feb 17; 74(2):975-83. PubMed ID: 16428743
    [Abstract] [Full Text] [Related]

  • 10. [Immunoprophylaxis and immunotherapy of experimental Pseudomonas aeruginosa sepsis].
    Grishina IA, Terekhova RP, Marchuk AI.
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Apr 17; (4):14-7. PubMed ID: 3087118
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Controlled trial of Pseudomonas immunoglobulin and vaccine in burn patients.
    Jones RJ, Roe EA, Gupta JL.
    Lancet; 1980 Dec 13; 2(8207):1263-5. PubMed ID: 6108445
    [Abstract] [Full Text] [Related]

  • 13. Motility, virulence, and protection with a flagella vaccine against Pseudomonas aeruginosa infection.
    Montie TC, Drake D, Sellin H, Slater O, Edmonds S.
    Antibiot Chemother (1971); 1987 Dec 13; 39():233-48. PubMed ID: 3118785
    [No Abstract] [Full Text] [Related]

  • 14. Anti-Pseudomonas immunoglobulin. III. Preliminary clinical evaluation.
    Sakiel S, Schiller B, Buchowicz I, Kotkowska-Tomanek E.
    Arch Immunol Ther Exp (Warsz); 1983 Dec 13; 31(4):517-21. PubMed ID: 6422901
    [Abstract] [Full Text] [Related]

  • 15. Immunization of burned patients against Pseudomonas aeruginosa infection at Safdarjang Hospital, New Delhi.
    Roe EA, Jones RJ.
    Rev Infect Dis; 1983 Dec 13; 5 Suppl 5():S922-30. PubMed ID: 6419315
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of the immune responses following co-administration of PilQ and type b-flagellin from Pseudomonas aeruginosa in the burn mouse model.
    Bakht Azad S, Nikokar I, Faezi S, Rasooly S, Mahdavi M.
    Microb Pathog; 2018 Oct 13; 123():426-432. PubMed ID: 30075242
    [Abstract] [Full Text] [Related]

  • 17. Antibody responses of burned patients immunized with a polyvalent Pseudomonas vaccine.
    Jones RJ.
    J Hyg (Lond); 1979 Jun 13; 82(3):453-62. PubMed ID: 109501
    [Abstract] [Full Text] [Related]

  • 18. Production and characterization of a human hyperimmune intravenous immunoglobulin against Pseudomonas aeruginosa and Klebsiella species.
    Cryz SJ, Fürer E, Sadoff JC, Fredeking T, Que JU, Cross AS.
    J Infect Dis; 1991 May 13; 163(5):1055-61. PubMed ID: 1902245
    [Abstract] [Full Text] [Related]

  • 19. The immunoprophylaxis and immunotherapy of Pseudomonas infections in burns with polyvalent Pseudomonas aeruginosa corpuscular vaccine.
    Ionescu A, Meitert E, Vasiliu S, Meitert T, Milicescu S, Sima F, Savulian C.
    Arch Roum Pathol Exp Microbiol; 1979 May 13; 38(3-4):317-30. PubMed ID: 122594
    [No Abstract] [Full Text] [Related]

  • 20. [Results of using a polyvalent vaccine against Pseudomonas aeruginosa in patients with burns treated at various therapeutic centers in Poland].
    Bukowska D, Serafińska D, Zietkiewicz W, Rudowski W, Hoffman S, Uszyński H, Molski M, Hess C, Jonecko A, Popiel D.
    Pol Tyg Lek; 1986 Dec 08; 41(49):1549-52. PubMed ID: 3108869
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.